Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03688204 · ClinicalTrials.gov registry record
Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer
A clinical trial, sponsored by Ambry Genetics.
- Completed
- Registry status
- 118
- Enrollment target
NCT03688204 is a clinical trial that has completed, run by Ambry Genetics. The registered enrollment target is 118 participants.
The verdict
NCT03688204 has completed, sponsored by Ambry Genetics.
- COMPLETED
- Registry status
- 118 participants
- Enrollment target
Study Summary
This study aims to assess how a polygenic risk score (PRS) reported with the results of multi-gene panel testing affects the breast cancer risk management recommendations healthcare providers make to their patients. The PRS is a score based on small genetic changes, clinical history, and family history. The PRS is used to estimate remaining lifetime risk of developing breast cancer for patients with no personal history of breast cancer and an overall negative result from MGPT.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2018-09-21 |
| Est. Completion | 2020-11-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03688204
The ClinicalTrials.gov registry entry for NCT03688204 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ambry Genetics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03688204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03688204 about?
NCT03688204 is a clinical study titled "Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer". This study aims to assess how a polygenic risk score (PRS) reported with the results of multi-gene panel testing affects the breast cancer risk management recommendations healthcare providers make to their patients. The PRS is a score based on small genetic changes, clinical history, and family hist...
What is the current status of trial NCT03688204?
This trial is currently completed. The enrollment target is 118 participants. The study started on 2018-09-21. Estimated completion is 2020-11-11.
Who is sponsoring clinical trial NCT03688204?
This trial is sponsored by Ambry Genetics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.